Phase 4 N=128 The Laparotomy Study
Gastrointestinal Cancer
Primary: Surgical Rating Score — 4; 4.75 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
Cocaine Dependence · Depression
Primary: Ln Benzoylecgonine Concentration — 9.8; 7.9 ln (ng/ml) — p=>0.05
Phase 2 N=28 Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction
Nicotine Dependence
Primary: Number of Days With Self-report of No Smoking and Breath Carbon Monoxide of <5 PPM During Quit-attempt Weeks — 0.2; 0 days — p=0.1
N/A N=14 Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Major Depressive Disorder
Primary: Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28) — 5 participants who met response criteria
N/A N=95 AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
Vascular Access Complication
Primary: Percentage of Participants With Successfully Inserted Peripheral IV Catheter Placement on First Attempt — 85.3 percentage of participants
Phase 2 N=452 A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Acute Kidney Injury
Primary: Incidence of Acute Kidney Injury (AKI) — 73; 18; 22; 71 Participants
N/A N=341 Prevalence of Pancreatic Cysts During Routine Endoscopic Ultra Sound
Pancreatic Cysts
Primary: Prevalence of Pancreatic Cysts During Routine EUS — 46 participants found to have a cyst
Phase 1 N=40 Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
Hookworm Infection · Hookworm Disease
Primary: Immediate Vaccine Related Adverse Events — 4; 1; 0; 1 Participants
N/A N=84 Concussion Testing: A Novel Non-invasive Concussion Detection Device
Concussion
Primary: A Measure Assessing the Sensitivity and Specificity Rate Based on the Nautilus Neurowave Data — 77; 87 percentage of participants
N/A N=219 Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)
Acute Mountain Sickness
Primary: Incidence of Acute Mountain Sickness — 18; 16 Participants
Phase 1 N=14 Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
HIV Infections
Primary: Percentage of Participants Who Experienced a Grade 3 or Higher Systemic (i.e., Not a Local Reaction) Adverse Event (AE) That is Possibly, Probably, or Definitely Related…
Phase 2 N=176 BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in the 7-Day Average Daily Pain Score Using an 11-Point Scale — 5.92; 6.09; 6.00; -1.68 score on a scale
N/A N=37 Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale - Suicidal Ideation (HDRS-SI) — 1.6; 1.6 units on a scale
N/A N=376 Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System
Diabetes
Primary: Percent of Self-Test Fingerstick Blood Glucose (BG) Results (From Subjects WITH Diabetes) Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory…
Phase 3 N=89 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)
Altitude Sickness
Primary: Acute Mountain Sickness — 19; 26 Participants